Abstract: Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.

Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and an ?-glycosidase inhibitor in the treatment of conditions and/or disorders related to hyperglycemia.

Abstract: Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.

Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and an ?-glycosidase inhibitor in the treatment of conditions and/or disorders related to hyperglycemia.

Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and insulin or an insulin analogue in the treatment of mellitus and/or disorders related to diabetes mellitus.

Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia.

Abstract: Novel crystal forms of (R)-(+)-verapamil hydrochloride are disclosed.

Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia.

Abstract: Novel crystal forms of (R)-(+)-verapamil hydrochloride are disclosed.

Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia.

Abstract: Novel crystal forms of (R)-(?)-verapamil hydrochloride are disclosed.

Abstract: Disclosed herein is an oral dosage formulation that contains both immediate-release and sustained release drugs for treating neurodegenerative disorders. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI) with a dissolution rate of releasing more than 80% of the AChEI within 60 min; and the sustained-release drug is memantine with a dissolution rate of releasing more than 80% of memantine within 12 hours.

Abstract: Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.

Abstract: Disclosed herein are methods and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L receptor. The method comprises administering a composition comprising an effective amount of verapamil and a pharmaceutically acceptable excipient to a subject, wherein the verapamil is capable of binding to at least one of a receptor selected from the group consisting of orexin receptor 1, orexin receptor 2, somatostatin receptor 2 and dopamine D2L receptor of the subject.

Abstract: Disclosed herein is an oral dosage formulation that contains both immediate-release and sustained release drugs for treating neurodegenerative disorders. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI) with a dissolution rate of releasing more than 80% of the AChEI within 60 min; and the sustained-release drug is memantine with a dissolution rate of releasing more than 80% of memantine within 12 hours.

Abstract: Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.